Erinma Elibe1, David Boyce-Fappiano1, Samuel Ryu2, M Salim Siddiqui1, Ian Lee3, Jack Rock3, Farzan Siddiqui1. 1. Department of Radiation Oncology, Henry Ford Hospital, 2799 W Grand Blvd Detroit, MI 48202, USA. 2. Department of Radiation Oncology, Stony Brook University School of Medicine, 101 Nicolls Rd, Stony Brook, NY 11794, USA. 3. Department of Neurosurgery, Henry Ford Hospital, 2799 W Grand Blvd Detroit, MI 48202, USA.
Abstract
PURPOSE: The purpose of this study was to evaluate the role of stereotactic radiosurgery in the treatment of primary tumors of the spine and spinal cord. METHODS: An Institutional Review Board approved retrospective analysis of 30 patients with primary spine tumors treated at a single institution was performed. Post-treatment pain, neurological, and radiographic responses were the endpoints. RESULTS: Nine patients were treated for benign tumors, and 21 patients were treated for malignant tumors. The median dose delivered was 16 Gy in one fraction. Median follow up was 13.13 months (range, 1 month-84 months). Pain relief was 88% initially. Pain recurred in five patients with a median time to recurrence of 5 months (range, 3.6 months - 80 months). Neurological improvement was achieved in 65% of patients. Three patients experienced a recurrence in their neurological deficit (at 3.6 months, 1.6 years, and 3.7 years after SRS). Radiographic control was achieved in 77% of sites treated with SRS. Thirteen of the treated sites recurred with a median time of 9.9 months. Two long-term toxicities were observed (asymptomatic radio-necrosis of the erector spinae muscle and foot drop). CONCLUSIONS: Our results suggest that SRS is a safe and effective treatment option for primary tumors of the spine and spinal cord.
PURPOSE: The purpose of this study was to evaluate the role of stereotactic radiosurgery in the treatment of primary tumors of the spine and spinal cord. METHODS: An Institutional Review Board approved retrospective analysis of 30 patients with primary spine tumors treated at a single institution was performed. Post-treatment pain, neurological, and radiographic responses were the endpoints. RESULTS: Nine patients were treated for benign tumors, and 21 patients were treated for malignant tumors. The median dose delivered was 16 Gy in one fraction. Median follow up was 13.13 months (range, 1 month-84 months). Pain relief was 88% initially. Pain recurred in five patients with a median time to recurrence of 5 months (range, 3.6 months - 80 months). Neurological improvement was achieved in 65% of patients. Three patients experienced a recurrence in their neurological deficit (at 3.6 months, 1.6 years, and 3.7 years after SRS). Radiographic control was achieved in 77% of sites treated with SRS. Thirteen of the treated sites recurred with a median time of 9.9 months. Two long-term toxicities were observed (asymptomatic radio-necrosis of the erector spinae muscle and foot drop). CONCLUSIONS: Our results suggest that SRS is a safe and effective treatment option for primary tumors of the spine and spinal cord.
Entities:
Keywords:
primary spine tumor; stereotactic body radiation therapy; stereotactic radiosurgery
Authors: Samuel Ryu; Fang Fang Yin; Jack Rock; Jingeng Zhu; Archie Chu; Eduard Kagan; Lisa Rogers; Munther Ajlouni; Mark Rosenblum; Jae Ho Kim Journal: Cancer Date: 2003-04-15 Impact factor: 6.860
Authors: Debraj Mukherjee; Kaisorn L Chaichana; Ziya L Gokaslan; Oran Aaronson; Joseph S Cheng; Matthew J McGirt Journal: J Neurosurg Spine Date: 2010-12-24
Authors: Alexander E Ropper; Kevin S Cahill; John W Hanna; Edward F McCarthy; Ziya L Gokaslan; John H Chi Journal: Neurosurgery Date: 2011-12 Impact factor: 4.654
Authors: Jian-Yue Jin; Qing Chen; Ryan Jin; Jack Rock; Joseph Anderson; Shidong Li; Benjamin Movsas; Samuel Ryu Journal: Technol Cancer Res Treat Date: 2007-04
Authors: Alexander E Ropper; Kevin S Cahill; John W Hanna; Edward F McCarthy; Ziya L Gokaslan; John H Chi Journal: Neurosurgery Date: 2012-01 Impact factor: 4.654
Authors: Robert L Dodd; Mi-Ryeong Ryu; Pimkhuan Kamnerdsupaphon; Iris C Gibbs; Steven D Chang; John R Adler Journal: Neurosurgery Date: 2006-04 Impact factor: 4.654
Authors: Linh M Duong; Bridget J McCarthy; Roger E McLendon; Therese A Dolecek; Carol Kruchko; Lynda L Douglas; Umed A Ajani Journal: Cancer Date: 2012-01-03 Impact factor: 6.860
Authors: Lindsay Hwang; Christian C Okoye; Ravi B Patel; Arjun Sahgal; Matthew Foote; Kristin J Redmond; Christoph Hofstetter; Rajiv Saigal; Mahmud Mossa-Basha; William Yuh; Nina A Mayr; Samuel T Chao; Eric L Chang; Simon S Lo Journal: J Radiosurg SBRT Date: 2019